David C Young

List of Publications by Year
in descending order

21 papers	457 citations	623734 14 h-index	713466 21 g-index
21 all docs	21 docs citations	21 times ranked	477 citing authors

#	Article	IF	Citations
1	The indispensable role of pharmacy services and medication therapy management in cystic fibrosis. Pediatric Pulmonology, 2022, 57, .	2.0	2
2	Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy. Journal of Cystic Fibrosis, 2022, 21, 339-343.	0.7	35
3	Pharmacokinetics of intermittent dosed intravenous vancomycin in adult persons with cystic fibrosis. Pediatric Pulmonology, 2022, 57, 2646-2651.	2.0	4
4	Understanding the expanding role of pharmacy services in outpatient cystic fibrosis care. Pediatric Pulmonology, 2021, 56, 1378-1385.	2.0	9
5	State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: III. Executive summary. Pediatric Pulmonology, 2021, 56, 1825-1837.	2.0	5
6	State of the art in cystic fibrosis pharmacologyâ€"Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Antiâ€methicillinâ€resistant Staphylococcus aureus (MRSA) antibiotics. Pediatric Pulmonology, 2020, 55, 33-57.	2.0	14
7	Survey of current treatment practices for venous thromboembolism in patients with cystic fibrosis. Pediatric Pulmonology, 2020, 55, 149-155.	2.0	4
8	Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations:â€¯ II. Therapies for allergic bronchopulmonary aspergillosis. Pediatric Pulmonology, 2020, 55, 3541-3572.	2.0	8
9	Patients and families experience with pharmacist care at cystic fibrosis foundation accredited clinics. Pediatric Pulmonology, 2019, 54, 1216-1224.	2.0	16
10	An Evaluation of Vancomycin Area Under the Curve Estimation Methods for Children Treated for Acute Pulmonary Exacerbations of Cystic Fibrosis Due to Methicillinâ€Resistant Staphylococcus aureus. Journal of Clinical Pharmacology, 2019, 59, 198-205.	2.0	15
11	Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	15
12	Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins update. Pediatric Pulmonology, 2017, 52, 863-865.	2.0	5
13	Utilization of antibiotics for methicillinâ€resistant Staphylococcus aureus infection in cystic fibrosis. Pediatric Pulmonology, 2015, 50, 552-559.	2.0	39
14	Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Pediatric Pulmonology, 2013, 48, 1047-1061.	2.0	51
15	Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium. Pediatric Pulmonology, 2013, 48, 1-7.	2.0	15
16	Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. Pediatric Pulmonology, 2013, 48, 211-220.	2.0	32
17	Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins. Pediatric Pulmonology, 2013, 48, 107-122.	2.0	46
18	Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary. Pediatric Pulmonology, 2013, 48, 525-537.	2.0	27

#	Article	IF	Citations
19	Population Pharmacokinetics of Intermittent Vancomycin in Children with Cystic Fibrosis. Pharmacotherapy, 2013, 33, 1288-1296.	2.6	41
20	Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. Pediatric Pulmonology, 2012, 47, 1147-1158.	2.0	35
21	A survey of the utilization of antiâ€pseudomonal betaâ€lactam therapy in cystic fibrosis patients. Pediatric Pulmonology, 2011, 46, 987-990.	2.0	39